{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:21:39Z","timestamp":1793931699794,"version":"4.8.0"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["AC23_1\/00006"],"award-info":[{"award-number":["AC23_1\/00006"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espana Ministerio de Ciencia e Innovacion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["TRANSCAN2022-784-114 FC AECC"],"award-info":[{"award-number":["TRANSCAN2022-784-114 FC AECC"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.addr.2025.115760","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:54:29Z","timestamp":1765526069000},"page":"115760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape"],"prefix":"10.1016","volume":"229","author":[{"given":"Ainara","family":"Salgado-Pascual","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Zalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Lasarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2025.115760_bb0005","first-page":"1","article-title":"Global, regional, and national burden of pancreatic cancer from 1990 To 2021, its attributable risk factors, and projections to 2050: a systematic analysis of the global burden of disease study 2021","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2025.115760_bb0010","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/cancers17101726","article-title":"The role of nanoparticles in therapy of real-world patients with pancreatic Cancer: a scoping review","volume":"17","author":"Konstantinidis","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115760_bb0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17474124.2024.2322648","article-title":"Next-generation therapies for pancreatic cancer","volume":"18","author":"Buckley","year":"2024","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2025.115760_bb0020","author":"Global Cancer","year":"2025","journal-title":"Observatory"},{"issue":"17","key":"10.1016\/j.addr.2025.115760_bb0025","first-page":"1","article-title":"Consensus, debate, and prospective on pancreatic cancer treatments","volume":"171","author":"Wang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1341079","article-title":"Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC","volume":"15","author":"Musiu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2025.115760_bb0035","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3390\/jcm14041129","article-title":"Current and emerging treatment options for pancreatic cancer: a comprehensive review","volume":"14","author":"Hayat","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2025.115760_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116492","article-title":"Overcoming therapy resistance in pancreatic cancer: new insights and future directions","volume":"229","author":"Espona-Fiedler","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2025.115760_bb0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"Hu","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2025.115760_bb0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.addr.2025.115760_bb0055","doi-asserted-by":"crossref","first-page":"LBA661","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA661","article-title":"NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil\/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-na\u00efve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)","volume":"41","author":"Wainberg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0060","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.2174\/0929867328666210319144347","article-title":"The emerging landscapes to drug delivery Systems for the Treatment of pancreatic Cancer","volume":"28","author":"Magri","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.addr.2025.115760_bb0065","first-page":"1","article-title":"Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer","volume":"5","author":"Bulle","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2025.115760_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174442","article-title":"The extracellular matrix in pancreatic cancer: description of a complex network and promising therapeutic options","volume":"13","author":"Ferrara","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115760_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70788","article-title":"Fibrotic fortresses and therapeutic Frontiers: pancreatic stellate cells and the extracellular matrix in pancreatic Cancer","volume":"14","author":"Sigirli","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.addr.2025.115760_bb0080","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1152\/physrev.00042.2019","article-title":"Microenvironmental determinants of pancreatic cancer","volume":"100","author":"Hessmann","year":"2020","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.addr.2025.115760_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194880","article-title":"Multiphasic heterogeneity of fibroblasts in the microenvironment of pancreatic ductal adenocarcinoma: dissection and the sum of the dynamics","volume":"14","author":"Ijichi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115760_bb0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/path.5224","article-title":"Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma","volume":"248","author":"Neuzillet","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.addr.2025.115760_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1557698","article-title":"Heterogenous cancer-associated fibroblasts related tumor microenvironment marked by CD10\/KLF4\/TIAM1 were identified in pancreatic adenocarcinoma by integrated transcriptomics","volume":"16","author":"Wan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2025.115760_bb0100","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.bpj.2016.03.040","article-title":"Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase","volume":"110","author":"Dufort","year":"2016","journal-title":"Biophys. J."},{"key":"10.1016\/j.addr.2025.115760_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113786","article-title":"Targeting tumor extracellular matrix with nanoparticles to circumvent therapeutic resistance","volume":"383","author":"Ding","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0110","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1053\/j.gastro.2016.03.040","article-title":"Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma","volume":"150","author":"Dufort","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2025.115760_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10671-w","article-title":"Collagen complexity spatially defines microregions of Total tissue pressure in pancreatic cancer","volume":"7","author":"Nieskoski","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115760_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.2012.569","article-title":"Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer","volume":"108","author":"Provenzano","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2025.115760_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176357","article-title":"Advance in the role of chemokines\/chemokine receptors in carcinogenesis: focus on pancreatic cancer","volume":"967","author":"Song","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.addr.2025.115760_bb0130","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41586-022-05169-z","article-title":"Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome","volume":"610","author":"Su","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115760_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132438","article-title":"Decoding the intricate landscape of pancreatic cancer: insights into tumor biology, microenvironment, and therapeutic interventions","volume":"16","author":"Argentiero","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115760_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.semcancer.2022.03.021","article-title":"Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment","volume":"86","author":"Bhatia","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.addr.2025.115760_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114357","article-title":"Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment","volume":"187","author":"Tarannum","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115760_bb0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","article-title":"KRAS mutation in pancreatic cancer","volume":"48","author":"Luo","year":"2021","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0155","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3390\/jcm13072103","article-title":"The clinical implications of KRAS mutations and variant allele frequencies in pancreatic ductal adenocarcinoma","volume":"13","author":"Nusrat","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2025.115760_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/cells13121061","article-title":"Down-regulation of AKT proteins slows the growth of mutant-KRAS pancreatic tumors","volume":"13","author":"Chen","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.addr.2025.115760_bb0165","first-page":"3279","article-title":"The role of akt activation in the response to chemotherapy in pancreatic cancer","volume":"30","author":"Parsons","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.addr.2025.115760_bb0170","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1158\/0008-5472.CAN-07-0175","article-title":"Dynamics of the immune reaction to pancreatic cancer from inception to invasion","volume":"67","author":"Clark","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115760_bb0175","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41392-021-00534-2","article-title":"Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2025.115760_bb0180","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1535-7163.MCT-23-0519","article-title":"KRAS-driven tumorigenesis and KRAS-driven therapy in pancreatic adenocarcinoma","volume":"23","author":"Than","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2025.115760_bb0185","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-11-0908","article-title":"STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis","volume":"71","author":"Corcoran","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115760_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep17663","article-title":"Multiple regulation pathways and pivotal biological functions of STAT3 in cancer","volume":"5","author":"Yuan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115760_bb0195","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/0008-5472.CAN-24-2330","article-title":"SMAD4 and KRAS status shapes cancer cell\u2013stromal cross-talk and therapeutic response in pancreatic cancer","volume":"85","author":"Lloyd","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115760_bb0200","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-24-1970","article-title":"SMAD4 deficiency promotes pancreatic Cancer progression and confers susceptibility to TGF\u03b2 inhibition","author":"Murimwa","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115760_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189220","article-title":"New insight into the role of SMAD4 mutation\/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas","volume":"1879","author":"Yao","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.addr.2025.115760_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103534","article-title":"SMAD4 and the TGF\u0392 pathway in patients with pancreatic ductal adenocarcinoma","volume":"21","author":"Dardare","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115760_bb0215","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1038\/s41388-022-02368-w","article-title":"Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer","volume":"41","author":"Datta","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2025.115760_bb0220","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/carcin\/bgad068","article-title":"An integrated analysis identifies six molecular subtypes of pancreatic ductal adenocarcinoma revealing cellular and molecular landscape","volume":"44","author":"Li","year":"2023","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.addr.2025.115760_bb0225","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4546-8","article-title":"Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes","volume":"18","author":"Zhao","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2025.115760_bb0230","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","article-title":"Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer","volume":"13","author":"Falcomat\u00e0","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115760_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09416-2","article-title":"Specialized dendritic cells induce tumor-promoting IL-10 + IL-17 + FoxP3 neg regulatory CD4 + T cells in pancreatic carcinoma","volume":"10","author":"Barilla","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115760_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55424-2","article-title":"Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms","volume":"16","author":"Sivakumar","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115760_bb0245","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.3390\/jcm13206185","article-title":"Assessing influence of mismatch repair mutations on survival in patients after resection of pancreatic ductal and periampullary adenocarcinoma","volume":"13","author":"Prezioso","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2025.115760_bb0250","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/tgh.2020.04.03","article-title":"Pancreatic cancer and immune checkpoint inhibitors\u2014still a long way to go","volume":"6","author":"Bian","year":"2021","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2025.115760_bb0255","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s12672-025-02873-w","article-title":"Hypoxia- and lactate metabolism-associated prognostic and therapeutic signature in pancreatic cancer","volume":"16","author":"Zhang","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0260","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/ijc.34367","article-title":"Crosstalk between tumor acidosis, p53 and extracellular matrix regulates pancreatic cancer aggressiveness","volume":"152","author":"Czaplinska","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2025.115760_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/cells13221924","article-title":"Emerging role of extracellular pH in tumor microenvironment as a therapeutic target for Cancer immunotherapy","volume":"13","author":"Rahman","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.addr.2025.115760_bb0270","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-physiol-021119-034627","article-title":"The acidic tumor microenvironment as a driver of cancer","volume":"82","author":"Boedtkjer","year":"2020","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.addr.2025.115760_bb0275","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02329-x","article-title":"Identification of distinct slow mode of reversible adaptation of pancreatic ductal adenocarcinoma to the prolonged acidic pH microenvironment","volume":"41","author":"Wu","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115760_bb0280","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0360-3016(00)00803-8","article-title":"Pancreatic tumors show high levels of hypoxia","volume":"48","author":"Koong","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.addr.2025.115760_bb0285","first-page":"1","article-title":"Targeting hypoxic tumor microenvironment in pancreatic cancer","volume":"141","author":"Tao","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0290","doi-asserted-by":"crossref","DOI":"10.1172\/JCI191940","article-title":"What's on the menu?: metabolic constraints in the pancreatic tumor microenvironment","volume":"135","author":"Sheehan","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2025.115760_bb0295","doi-asserted-by":"crossref","DOI":"10.1172\/JCI187024","article-title":"Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma","volume":"135","author":"Sun","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2025.115760_bb0300","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191920","article-title":"Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic cd8+ t cells","volume":"217","author":"Manzo","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2025.115760_bb0305","doi-asserted-by":"crossref","first-page":"9594","DOI":"10.1021\/acsnano.7b04855","article-title":"Bridging bio-nano science and cancer nanomedicine","volume":"11","author":"Bj\u00f6rnmalm","year":"2017","journal-title":"ACS Nano"},{"issue":"20","key":"10.1016\/j.addr.2025.115760_bb0310","first-page":"1","article-title":"Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists","volume":"201","author":"Joudeh","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2025.115760_bb0315","first-page":"1","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2025.115760_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2025.1548588","article-title":"Nanotechnology in cancer treatment: revolutionizing strategies against drug resistance","volume":"13","author":"Sabir","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2025.115760_bb0325","first-page":"1","article-title":"Lipid-based nanosystems: the next generation of cancer immune therapy","volume":"171","author":"Cheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0330","article-title":"Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment","volume":"32","author":"Lin","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.addr.2025.115760_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1983","article-title":"Theranostic nanoparticles for detection and treatment of pancreatic cancer","volume":"16","author":"Agarwal","year":"2024","journal-title":"Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology."},{"key":"10.1016\/j.addr.2025.115760_bb0340","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0345","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3390\/biom12060784","article-title":"Nano-based approved Pharmaceuticals for Cancer Treatment: present and future challenges","volume":"12","author":"Rodr\u00edguez","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.addr.2025.115760_bb0350","series-title":"European Medicines Agency (EMA)","author":"Pazenir","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0355","series-title":"European Medicines Agency (EMA)","author":"Vyxeos liposomal (previously Vyxeos)","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0360","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40265-024-02133-1","article-title":"Liposomal irinotecan: a review as first-line therapy in metastatic pancreatic adenocarcinoma","volume":"85","author":"Brown","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2025.115760_bb0365","series-title":"Onivyde pegylated liposomal (previously Onivyde)","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0375","series-title":"Mepact","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0380","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/pharmaceutics17060779","article-title":"Surfactant-enabled nanocarriers in breast Cancer therapy: targeted delivery and multidrug resistance reversal","volume":"17","author":"Jadhav","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2025.115760_bb0385","series-title":"Oncaspar","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0390","series-title":"Abraxane","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0395","first-page":"21","year":"2025","journal-title":"NDA"},{"key":"10.1016\/j.addr.2025.115760_bb0400","first-page":"50","volume":"2","year":"1996","journal-title":"AIDS Care"},{"key":"10.1016\/j.addr.2025.115760_bb0405","article-title":"Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): an updated analysis and future perspective","volume":"4","author":"Gabizon","year":"2025","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0410","series-title":"Caelyx pegylated liposomal","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0415","series-title":"Myocet liposomal (previously Myocet)","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0420","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ygyno.2016.02.033","article-title":"Equivalency challenge: evaluation of Lipodox\u00ae as the generic equivalent for Doxil\u00ae in a human ovarian cancer orthotropic mouse model","volume":"141","author":"Smith","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0425","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.2147\/IJN.S500997","article-title":"Wolf in sheep&rsquo;s clothing: taming Cancer&rsquo;s resistance with human serum albumin?","volume":"20","author":"Stukan","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2025.115760_bb0430","doi-asserted-by":"crossref","first-page":"v6","DOI":"10.1093\/annonc\/mdt322","article-title":"Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India","volume":"24","author":"Ranade","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0435","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/pharmaceutics15030774","article-title":"Approved nanomedicine against diseases","volume":"15","author":"Jia","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2025.115760_bb0440","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jconrel.2012.09.006","article-title":"Liposomal paclitaxel formulations","volume":"163","author":"Koudelka","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0450","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201606628","article-title":"Rational design of cancer nanomedicine: nanoproperty integration and synchronization","volume":"29","author":"Sun","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2025.115760_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012560","article-title":"Physiologically based pharmacokinetic Modeling of nanoparticle biodistribution: a review of existing models, simulation software, and data analysis tools","volume":"23","author":"Kutumova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115760_bb0460","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2022.09.002","article-title":"Stealth nanoparticles in oncology: facing the PEG dilemma","volume":"351","author":"Zalba","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0465","article-title":"Exploring and Analyzing the systemic delivery barriers for nanoparticles","volume":"34","author":"Wang","year":"2023","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.addr.2025.115760_bb0470","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jconrel.2022.09.031","article-title":"Polyethylene glycol (PEG): the nature, immunogenicity, and role in the hypersensitivity of PEGylated products","volume":"351","author":"Ibrahim","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0475","first-page":"1377","article-title":"Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA, nanomedicine nanotechnology","volume":"13","author":"Kulkarni","year":"2017","journal-title":"Biol. Med."},{"key":"10.1016\/j.addr.2025.115760_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114726","article-title":"From in vitro to in vivo: the dominant role of PEG-lipids in LNP performance","volume":"212","author":"Borah","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2025.115760_bb0485","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","volume":"31","author":"Varghese","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115760_bb0490","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1158\/1535-7163.MCT-24-0266","article-title":"Novel amanitin-based antibody\u2013drug conjugates targeting TROP2 for the treatment of pancreatic cancer","volume":"24","author":"Papacharisi","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"7963","key":"10.1016\/j.addr.2025.115760_bb0495","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115760_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123293","article-title":"pH-triggered \u201cPEG\u201d sheddable and folic acid-targeted nanoparticles for docetaxel delivery in breast cancer treatment","volume":"644","author":"Sui","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115760_bb0505","doi-asserted-by":"crossref","DOI":"10.1080\/17435889.2025.2500917","article-title":"The benefits of emerging alternatives to PEG for lipid nanoparticle RNA delivery systems","author":"Berger","year":"2025","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2025.115760_bb0510","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/polym12020298","article-title":"The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Thi","year":"2020","journal-title":"Polym"},{"key":"10.1016\/j.addr.2025.115760_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113824","article-title":"Biomimetic nanosystems for pancreatic cancer therapy: a review","volume":"383","author":"Pereira-Silva","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0520","doi-asserted-by":"crossref","DOI":"10.1039\/D4TB02206H","article-title":"A biomimetic dual-targeting nanomedicine for pancreatic cancer therapy","volume":"13","author":"Zhou","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2025.115760_bb0525","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-024-02843-5","article-title":"Stealth nanocarriers in Cancer therapy: a comprehensive review of design, functionality, and clinical applications","volume":"25","author":"Saadh","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2025.115760_bb0530","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01535-8","article-title":"Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy","volume":"17","author":"Lu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0535","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/10717544.2018.1474965","article-title":"Temporary suppression the sequestrated function of host macrophages for better nanoparticles tumor delivery","volume":"25","author":"Hao","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2025.115760_bb0540","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1111\/liv.15441","article-title":"Regulation of the macrophage-hepatic stellate cell interaction by targeting macrophage peroxisome proliferator-activated receptor gamma to prevent non-alcoholic steatohepatitis progression in mice","volume":"42","author":"Ni","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.addr.2025.115760_bb0545","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1021\/acs.nanolett.0c00752","article-title":"A Nanoprimer to improve the systemic delivery of siRNA and mRNA","volume":"20","author":"Saunders","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2025.115760_bb0550","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jconrel.2022.04.031","article-title":"Advocation and advancements of EPR effect theory in drug delivery science: a commentary","volume":"346","author":"Hashida","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0555","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jconrel.2023.07.039","article-title":"Targeting endothelial permeability in the EPR effect","volume":"361","author":"Lahooti","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114708","article-title":"Nanoparticle biodistribution coefficients: a quantitative approach for understanding the tissue distribution of nanoparticles","volume":"194","author":"Kumar","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115760_bb0565","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2025.115760_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103045","article-title":"Progress and challenges in the translation of cancer nanomedicines","volume":"85","author":"Tong","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.addr.2025.115760_bb0575","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s44222-024-00154-9","article-title":"The mechanisms of nanoparticle delivery to solid tumours","volume":"2","author":"Nguyen","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.addr.2025.115760_bb0580","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-bioeng-071811-150124","article-title":"The effect of nanoparticle size, shape, and surface chemistry on biological systems","volume":"14","author":"Albanese","year":"2012","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.addr.2025.115760_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123315","article-title":"Strategies to enhance the penetration of nanomedicine in solid tumors","volume":"321","author":"Liu","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2025.115760_bb0595","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202002253","article-title":"Sequential modulations of tumor vasculature and stromal barriers augment the active targeting efficacy of antibody-modified Nanophotosensitizer in desmoplastic ovarian carcinoma","volume":"8","author":"Yan","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2025.115760_bb0600","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: from vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2025.115760_bb0605","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jconrel.2022.03.043","article-title":"Strategies to improve the EPR effect: a mechanistic perspective and clinical translation","volume":"345","author":"Ikeda-Imafuku","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-025-02368-w","article-title":"Nanomedicine in cancer therapeutics: current perspectives from bench to bedside","volume":"24","author":"Abdullah","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2025.115760_bb0615","doi-asserted-by":"crossref","DOI":"10.1080\/17425247.2024.2412245","article-title":"Nanomedicines modulate the tumor immune microenvironment for cancer therapy","author":"Chao","year":"2024","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2025.115760_bb0620","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1021\/acsnano.9b02395","article-title":"Collagenase nanoparticles enhance the penetration of drugs into pancreatic Tumors","volume":"13","author":"Zinger","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2025.115760_bb0625","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ijc.33985","article-title":"Targeting type I collagen for cancer treatment","volume":"151","author":"Shi","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2025.115760_bb0630","doi-asserted-by":"crossref","first-page":"906","DOI":"10.7150\/thno.47446","article-title":"Collagenase IV and clusterin-modified polycaprolactone-polyethylene glycol nanoparticles for penetrating dense tumor tissues","volume":"11","author":"Huang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2025.115760_bb0635","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2014.05.019","article-title":"Improving the distribution of Doxil\u00ae in the tumormatrix by depletion of tumor hyaluronan","volume":"191","author":"Kohli","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0640","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.2147\/IJN.S504503","article-title":"Extensive review of nanomedicine strategies targeting the tumor microenvironment in PDAC","volume":"20","author":"Liu","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2025.115760_bb0645","doi-asserted-by":"crossref","first-page":"19793","DOI":"10.1021\/acsnano.3c03838","article-title":"Dual enzyme Cascade-activated popcorn-like nanoparticles efficiently Remodeled stellate cells to alleviate pancreatic desmoplasia","volume":"17","author":"Cao","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2025.115760_bb0650","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05906-x","article-title":"Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem","volume":"9","author":"Han","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115760_bb0655","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.addr.2025.115760_bb0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115760_bb0665","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","article-title":"The interplay between extracellular matrix Remodeling and Cancer therapeutics","volume":"14","author":"Prakash","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115760_bb0670","series-title":"Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer, Pancreas (Fairfax, Va.)","first-page":"e1","volume":"3","author":"Hakim","year":"2019"},{"key":"10.1016\/j.addr.2025.115760_bb0675","doi-asserted-by":"crossref","first-page":"355","DOI":"10.7150\/thno.29137","article-title":"Chemotherapy priming of the pancreatic tumor microenvironment promotes delivery and anti-metastasis efficacy of intravenous low-molecular-weight heparin-coated lipid-siRNA complex","volume":"9","author":"Yu","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2025.115760_bb0680","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.omto.2022.02.022","article-title":"Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer","volume":"24","author":"Kim","year":"2022","journal-title":"Mol. Ther. Oncolytics."},{"key":"10.1016\/j.addr.2025.115760_bb0685","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1021\/acsbiomaterials.8b01600","article-title":"Sequential drug release to modulate collagen synthesis and promote micelle penetration in Tumors","volume":"5","author":"Chen","year":"2019","journal-title":"ACS Biomater Sci. Eng."},{"key":"10.1016\/j.addr.2025.115760_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-bioeng-071811-150124","article-title":"The effect of nanoparticle size, shape, and surface chemistry on biological systems","volume":"14","author":"Albanese","year":"2012","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.addr.2025.115760_bb0695","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2018.03.012","article-title":"Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles","volume":"277","author":"Niu","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105693","article-title":"Size-shrinkable and protein kinase c\u03b1-recognizable nanoparticles for deep tumor penetration and cellular internalization","volume":"159","author":"Ma","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2025.115760_bb0705","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201701170","article-title":"Sequentially responsive Shell-stacked nanoparticles for deep penetration into solid Tumors","volume":"29","author":"Chen","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2025.115760_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.576420","article-title":"Tumor-microenvironment- responsive size-shrinkable drug-delivery Nanosystems for deepened penetration into Tumors","volume":"7","author":"Cheng","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.addr.2025.115760_bb0715","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jconrel.2020.01.035","article-title":"Functionalizing nanoparticles with cancer-targeting antibodies: a comparison of strategies","volume":"320","author":"Marques","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0720","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jconrel.2018.02.015","article-title":"Immunoliposomes in clinical oncology: state of the art and future perspectives","volume":"275","author":"Merino","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0725","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2025.115760_bb0730","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","article-title":"Targeting cancer with mRNA\u2013lipid nanoparticles: key considerations and future prospects","volume":"20","author":"Kon","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0735","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01320-5","article-title":"Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies","volume":"15","author":"Tian","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0740","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.2147\/IJN.S504503","article-title":"Extensive review of nanomedicine strategies targeting the tumor microenvironment in PDAC","volume":"20","author":"Liu","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2025.115760_bb0745","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/cgt.2013.9","article-title":"Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy","volume":"20","author":"Camp","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.addr.2025.115760_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216810","article-title":"Biodistribution and therapeutic efficacy of a gold nanoparticle-based targeted drug delivery system against pancreatic cancer","volume":"589","author":"Elechalawar","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2025.115760_bb0755","doi-asserted-by":"crossref","first-page":"11647","DOI":"10.1039\/D0NR02387F","article-title":"Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer cells","volume":"12","author":"Greene","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2025.115760_bb0760","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1515\/nanoph-2021-0304","article-title":"Photodynamic priming with triple-receptor targeted nanoconjugates that trigger T cell-mediated immune responses in a 3D in vitro heterocellular model of pancreatic cancer","volume":"10","author":"De Silva","year":"2021","journal-title":"Nanophotonics"},{"key":"10.1016\/j.addr.2025.115760_bb0765","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1021\/acsabm.0c01443","article-title":"Nanomechanical insight of pancreatic Cancer cell membrane during receptor mediated endocytosis of targeted gold nanoparticles","volume":"4","author":"Kulkarni","year":"2021","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.addr.2025.115760_bb0770","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.2147\/IJN.S295740","article-title":"Aptamer-targeted calcium phosphosilicate nanoparticles for effective imaging of pancreatic and prostate cancer","volume":"16","author":"Abraham","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2025.115760_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113588","article-title":"Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic ductal adenocarcinoma","volume":"381","author":"Shen","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0780","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ebiom.2018.03.008","article-title":"Plectin-1 targeted dual-modality nanoparticles for pancreatic cancer imaging","volume":"30","author":"Chen","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2025.115760_bb0785","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2023.03.016","article-title":"Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors","volume":"357","author":"Anthiya","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0790","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.apsb.2018.12.009","article-title":"Neutrophil-mimicking therapeutic nanoparticles for targeted chemotherapy of pancreatic carcinoma","volume":"9","author":"Cao","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2025.115760_bb0795","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.7150\/thno.38069","article-title":"Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics","volume":"10","author":"Mi","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2025.115760_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113878","article-title":"Rational design of stimuli responsive nanoparticle systems for the controlled, intracellular delivery of immunotherapeutic and chemotherapeutic agents","volume":"384","author":"Huang","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0805","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2464189","article-title":"Synergistic effect of pH-sensitive PEGylated RG3-chitosan prodrug nanoparticles encapsulated celastrol on pancreatic cancer","volume":"32","author":"Zhang","year":"2025","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2025.115760_bb0810","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1039\/D0TB00017E","article-title":"Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy","volume":"8","author":"Wang","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2025.115760_bb0815","doi-asserted-by":"crossref","first-page":"23737","DOI":"10.1021\/acsami.0c05308","article-title":"Magnetic targeting and ultrasound activation of liposome-microbubble conjugate for enhanced delivery of anticancer therapies","volume":"12","author":"Dwivedi","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2025.115760_bb0820","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2025.115760_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103041","article-title":"Biological recognition and cellular trafficking of targeted RNA-lipid nanoparticles","volume":"85","author":"Escalona-Rayo","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.addr.2025.115760_bb0830","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2025.115760_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115446","article-title":"Breaking the final barrier: evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome","volume":"214","author":"Mrksich","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115760_bb0840","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jconrel.2024.08.030","article-title":"Enhancing RNA-lipid nanoparticle delivery: organ- and cell-specificity and barcoding strategies","volume":"375","author":"Wei","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0845","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/nnm-2018-0326","article-title":"Controlling endosomal escape using nanoparticle composition: current progress and future perspectives","volume":"14","author":"Cupic","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2025.115760_bb0850","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1452","article-title":"Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles","volume":"9","author":"Selby","year":"2017","journal-title":"Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology."},{"key":"10.1016\/j.addr.2025.115760_bb0855","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.addr.2020.09.009","article-title":"Polymeric micelles for the delivery of poorly soluble drugs: from nanoformulation to clinical approval","volume":"156","author":"Hwang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115760_bb0860","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00280-015-2833-5","article-title":"Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration","volume":"76","author":"Chen","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2025.115760_bb0865","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115760_bb0870","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"Nab-paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb0875","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115760_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116685","article-title":"Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy","volume":"232","author":"Escalera-Anzola","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2025.115760_bb0885","series-title":"ONIVYDE\u00ae (irinotecan liposome injection) \u00ad- Official HCP Site","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0900","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-02-1441","article-title":"Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma","volume":"10","author":"Yamamoto","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115760_bb0910","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-10829-y","article-title":"Phase I\/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)","volume":"23","author":"Thivat","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2025.115760_bb0925","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115760_bb0940","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00428-023-03570-1","article-title":"Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations","volume":"483","author":"Navale","year":"2023","journal-title":"Virchows Arch."},{"key":"10.1016\/j.addr.2025.115760_bb0950","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.addr.2020.07.027","article-title":"Development of Promitil\u00ae, a lipidic prodrug of mitomycin c in PEGylated liposomes: from bench to bedside","volume":"154\u2013155","author":"Gabizon","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115760_bb0955","series-title":"Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0960","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.tig.2023.08.003","article-title":"Take a walk on the KRAB side","volume":"39","author":"Rosspopoff","year":"2023","journal-title":"Trends Genet."},{"key":"10.1016\/j.addr.2025.115760_bb0965","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13402-020-00526-4","article-title":"DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications","volume":"43","author":"Wong","year":"2020","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.addr.2025.115760_bb0970","series-title":"Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO\u2122 I Trial - BioSpace","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0975","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.2147\/CMAR.S199257","article-title":"MiR-193a-3p inhibits pancreatic ductal adenocarcinoma cell proliferation by targeting CCND1","volume":"11","author":"Chen","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.addr.2025.115760_bb0980","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-52202-y","article-title":"Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models","volume":"15","author":"Senapedis","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115760_bb0985","series-title":"First-in-human phase 1\/2 study (MYCHELANGELO I) of first-in-class epigenomic controller OTX-2002 targeting MYC oncogene in patients with hepatocellular carcinoma (HCC) and other solid tumors. - ASCO","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb0990","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102108","article-title":"Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma","volume":"47","author":"Mas","year":"2023","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.addr.2025.115760_bb0995","series-title":"Myeloid Therapeutics Initiates Patient Dosing with MT-302, a Novel TROP2-Targeting RNA CAR, in Phase 1 Study for Advanced or Metastatic Epithelial Tumors - Myeloid Therapeutics","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb1000","series-title":"Definition of AKT-1 antisense oligonucleotide WGI-0301 - NCI Drug Dictionary - NCI","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb1005","series-title":"Abogenbio","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb1010","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99263","article-title":"Generation and testing of clinical-grade exosomes for pancreatic cancer","volume":"3","author":"Mendt","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.addr.2025.115760_bb1015","series-title":"Immix Doses First Patient in USA in its Phase 1b\/2a Trial in Patients with Advanced Solid Tumors - IMMIX BIOPHARMA INC","year":"2025"},{"key":"10.1016\/j.addr.2025.115760_bb1020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-3-031-92033-2_18","article-title":"Iron and Cancer","volume":"1480","author":"Torti","year":"2025","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.addr.2025.115760_bb1025","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1172\/JCI136760","article-title":"Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix","volume":"130","author":"Jiang","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2025.115760_bb1030","article-title":"Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice","author":"Serrano","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.addr.2025.115760_bb1035","doi-asserted-by":"crossref","first-page":"25134","DOI":"10.1021\/acsnano.5c05395","article-title":"Reprogramming immunodeficiency in lung metastases via PD-L1 siRNA delivery and antigen capture of Nanosponge-mediated dendritic cell modulation","volume":"19","author":"Huynh","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2025.115760_bb1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2025.102838","article-title":"Wireless chargeable gold Yarnball-mediated mitochondrial depolarization for dendritic cell detainment in programmed brain tumor immunotherapy","volume":"65","author":"Moorthy","year":"2025","journal-title":"Nano Today"},{"key":"10.1016\/j.addr.2025.115760_bb1045","doi-asserted-by":"crossref","first-page":"18712","DOI":"10.1021\/acsnano.4c06183","article-title":"A self-Cascade penetrating brain tumor immunotherapy mediated by near-infrared II cell membrane-disrupting nanoflakes via detained dendritic cells","volume":"18","author":"Yalamandala","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2025.115760_bb1050","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-024-01754-7","article-title":"A translational framework to DELIVER nanomedicines to the clinic","volume":"19","author":"Joyce","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2025.115760_bb1055","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41565-018-0246-4","article-title":"Minimum information reporting in bio\u2013nano experimental literature","volume":"13","author":"Faria","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2025.115760_bb1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113731","article-title":"Cancer nanomedicine from a clinician-scientist perspective: lessons and prospects","volume":"382","author":"Gabizon","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115760_bb1065","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00604-025-07286-8","article-title":"Next-generation cancer therapeutics: unveiling the potential of liposome-based nanoparticles through bioinformatics","volume":"192","author":"Irfan","year":"2025","journal-title":"Mikrochim. Acta"},{"key":"10.1016\/j.addr.2025.115760_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2024.09.015","article-title":"Review of machine learning for lipid nanoparticle formulation and process development","volume":"113","author":"Dorsey","year":"2024","journal-title":"J. Pharm. Sci."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25002455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25002455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:53:27Z","timestamp":1781600007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X25002455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":204,"alternative-id":["S0169409X25002455"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2025.115760","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2025.115760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115760"}}